FTC affirms cancer cures case ruling
This article was originally published in The Tan Sheet
Executive Summary
Daniel Chapter One must notify customers it made deceptive and unsubstantiated cancer cure claims for its herbal products after failing in its appeal of an administrative law judge's ruling to uphold Federal Trade Commission charges. The commission's unanimous 1opinion, announced Dec. 24, says respondents Daniel Chapter One and James Feijo "lacked a reasonable basis to substantiate" claims their products BioShark, 7 Herb Formula and others inhibit tumor growth and are effective cancer treatments. Like other companies charged in FTC's 2008 enforcement sweep against bogus cancer cure claims, Providence, R.I.-based Daniel Chapter One is enjoined from making such claims without supporting scientific evidence (2"The Tan Sheet" Aug. 17, 2009, In Brief)
You may also be interested in...
Herbal Firm Denied Supreme Court Hearing Over Cancer Claim
The Supreme Court will not consider herbal supplement marketer Daniel Chapter One's argument that the right to freedom of religion allows the firm to claim its products cure cancer.
Judge throws book at Daniel Chapter One
An administrative judge upholds the Federal Trade Commission's charges that supplement marketer Daniel Chapter One falsely advertised its shark cartilage and herbal formulations prevent, treat and cure cancer. The judge found the firm could not substantiate its claims with reliable scientific evidence and ordered the company to stop making false claims. FTC charged Daniel Chapter One with deceptive advertising in 2008 in an enforcement sweep that charged 11 firms with marketing false cancer remedies (1"The Tan Sheet" Sept. 22, 2008)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.